777,880 Shares in Geron Corporation $GERN Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP acquired a new stake in Geron Corporation (NASDAQ:GERN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 777,880 shares of the biopharmaceutical company’s stock, valued at approximately $1,027,000. Geron comprises 0.8% of Seven Fleet Capital Management LP’s holdings, making the stock its 23rd biggest position. Seven Fleet Capital Management LP owned approximately 0.12% of Geron as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in GERN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Geron by 2.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock worth $627,000 after acquiring an additional 8,123 shares during the period. E Fund Management Co. Ltd. lifted its position in Geron by 12.0% in the second quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 9,849 shares during the period. LCM Capital Management Inc boosted its holdings in Geron by 80.6% in the 4th quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 10,000 shares in the last quarter. Velan Capital Investment Management LP boosted its holdings in Geron by 14.3% in the 3rd quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Swiss Life Asset Management Ltd increased its position in Geron by 73.6% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 11,182 shares during the period. 73.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Geron presently has an average rating of “Hold” and a consensus target price of $2.50.

Geron Trading Up 2.4%

Shares of GERN stock opened at $1.26 on Friday. The company has a current ratio of 6.78, a quick ratio of 4.96 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $808.32 million, a price-to-earnings ratio of -11.45 and a beta of 0.60. The firm has a 50-day moving average price of $1.39 and a 200 day moving average price of $1.44. Geron Corporation has a twelve month low of $1.04 and a twelve month high of $2.01.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.The firm had revenue of $51.84 million for the quarter, compared to analyst estimates of $50.59 million. Research analysts forecast that Geron Corporation will post -0.02 earnings per share for the current fiscal year.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.